Journal of International Oncology ›› 2025, Vol. 52 ›› Issue (3): 180-185.doi: 10.3760/cma.j.cn371439-20250110-00028

• Review • Previous Articles     Next Articles

Research progress of peripheral blood biomarkers in immunotherapy of non-small cell lung cancer

Wang Zhiying, Sheng Lijun()   

  1. Fifth Department of Oncology,Third Affiliated Hospital of Shandong First Medical University,Jinan 250031,China
  • Received:2025-01-10 Revised:2025-02-17 Online:2025-03-08 Published:2025-04-02
  • Contact: Sheng Lijun,Email:shenglijun328@126.com

Abstract:

Immunotherapy has achieved relatively satisfactory results in the treatment of non-small cell lung cancer (NSCLC),but not all patients can benefit from immunotherapy. Peripheral blood-based markers are easily accessible and can be monitored dynamically. Peripheral blood tumor cell-related markers (circulating tumor DNA,circulating tumor cells,peripheral blood tumor mutation load,exosomes,etc.),as well as immune and inflammatory markers (T-lymphocyte subpopulations,hematology-associated ratios,C-reactive protein,etc.) have demonstrated great potential in immunotherapy efficacy prediction,prognosis evaluation,and dynamic monitoring.

Key words: Carcinoma, non-small-cell lung, Biomarkers, tumor, Immunotherapy